# Signals Article: Exploring P31749 as a Putative Target for Triple Negative Breast Cancer
Background
P31749, also known as the putative target candidate, has emerged as a potential therapeutic target in the context of triple negative breast cancer (TNBC). This aggressive subtype of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors, presents significant treatment challenges due to limited targeted therapies. The exploration of P31749 may provide new avenues for intervention, warranting further investigation into its biological role and therapeutic implications.Data-mining rationale
The rationale for investigating P31749 stems from a comprehensive data-mining effort that cross-referenced UniProt's reviewed human entries related to "triple negative breast cancer" against 253 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, P31749 was identified in several expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical programs. This observation highlights a potential gap in the current understanding of its role in TNBC, suggesting that P31749 may be a candidate worthy of further exploration.Why prior analyses may have missed this
Many of the GEO datasets that include P31749 predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which is critical for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P31749's significance in TNBC. By re-analyzing these datasets with contemporary statistical approaches, it is plausible that the relevance of P31749 could be more clearly elucidated.Reasoning for further validation
To substantiate the potential role of P31749 in TNBC, several experimental approaches are proposed:1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes associated with P31749.
2. **Validate the top differentially-expressed genes** identified in the re-analysis by conducting quantitative PCR (qPCR) in an independent cohort of TNBC samples to confirm their expression patterns.
3. **Check tissue specificity** of P31749 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a target in TNBC versus other tissues.
4. **Run pathway context analyses** using tools like STRING or OmniPath to explore the biological pathways associated with P31749 and its potential interactions with other proteins involved in TNBC.
5. **If validated, assess druggability** of P31749 through databases such as DGIdb and ChEMBL to evaluate the feasibility of developing therapeutic agents targeting this candidate.
References
- UniProt. P31749. [UniProt](https://www.uniprot.org/uniprot/P31749)
- NCBI GEO. GDS:200327047, GDS:200267169, GDS:200305009, GDS:200128468, GDS:200294944. [GEO](https://www.ncbi.nlm.nih.gov/geo/)
- Limma package for R. [Bioconductor](https://bioconductor.org/packages/release/bioc/html/limma.html)
- Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)*, 57(1), 289-300. DOI: 10.1111/j.2517-6161.1995.tb02031.x
*This article is AI-curated commentary and does not claim peer-review status.*